Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21648Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:16:21Z | - |
| dc.date.available | 2015-11-24T19:16:21Z | - |
| dc.identifier.issn | 1368-5031 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21648 | - |
| dc.rights | Default Licence | - |
| dc.subject | Anticholesteremic Agents/*adverse effects/therapeutic use | en |
| dc.subject | Azetidines/*adverse effects/therapeutic use | en |
| dc.subject | Drug Interactions | en |
| dc.subject | Drug-Induced Liver Injury | en |
| dc.subject | Humans | en |
| dc.subject | Hypercholesterolemia/*drug therapy | en |
| dc.subject | Muscular Diseases/chemically induced | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Ezetimibe-associated adverse effects: what the clinician needs to know | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1111/j.1742-1241.2007.01592.x | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18173814 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1742-1241.2007.01592.x/asset/j.1742-1241.2007.01592.x.pdf?v=1&t=h0td6icq&s=d1ab208d758436756a7de35ca3e9a5f4fc75244a | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | OBJECTIVE: Ezetimibe is a relatively new lipid lowering agent, which is indicated for the treatment of primary hypercholesterolaemia, either as monotherapy or in combination with other hypolipidaemic drugs. The objective of the present article was to review the side effects attributed to ezetimibe administration and discuss their possible underlying mechanisms. Moreover, we aimed to comment on the possible drug interactions of ezetimibe and present current guidelines regarding its safe use. METHODS: Relevant articles were identified through a PubMed search (up to June 2007). RESULTS: Compelling evidence from the majority of the data reviewed here showed that adverse effects associated with ezetimibe use are few and mild without having been associated with serious clinical outcomes. In most studies ezetimibe has not been associated with increased rates of myopathy or rhabdomyolysis, whether used alone or in combination with statins, although there have been some case reports of myopathy attributed to this agent. Moreover, ezetimibe has been associated with mild elevations of liver transaminases, mainly in combination with a statin. Other side effects are extremely rare. It should be noted, however, there are no long-term safety data or outcome studies for ezetimibe yet. CONCLUSIONS: Ezetimibe is a safe alternative option for hyperlipidaemic patients intolerant to other lipid lowering drugs as well as a beneficial supplementary agent for patients who do not reach the recommended serum cholesterol level with their current hypolipidaemic treatment. However, as is the case with all new medications, physicians should be alert to recognise adverse effects associated with ezetimibe and report them to regulatory authorities. | en |
| heal.journalName | Int J Clin Pract | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Florentin-2008-Ezetimibe-associated.pdf | 179.24 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
